SVB Leerink analyst Danielle Antalffy maintains NeuroPace (NASDAQ:NPCE) with a Outperform and lowers the price target from $15 to $12.
Pfizer, BioNTech Initiate Rolling Submission Of Supplemental Biologics License Application To U.S. FDA For Booster Dose Of COMIRNATY In Individuals 16 And Older
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
New Phase 3 data show booster (third) dose of
